Drugs that contain Zoledronic Acid
1. Reclast patents expiration
RECLAST's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US4939130 | SANDOZ | Substituted alkanediphosphonic acids and pharmaceutical use |
Sep, 2012
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4939130 (Pediatric) | SANDOZ | Substituted alkanediphosphonic acids and pharmaceutical use |
Mar, 2013
(11 years ago) | |
| US8052987 | SANDOZ | Method of administering bisphosphonates |
Oct, 2023
(5 months ago) | |
| US7932241 | SANDOZ | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(3 years from now) | |
|
US7932241 (Pediatric) | SANDOZ | Pharmaceutical products comprising bisphosphonates |
Aug, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-595) | May 29, 2012 |
| New Indication(I-581) | Dec 19, 2011 |
| New Indication(I-584) | Mar 15, 2012 |
Market Authorisation Date: 16 April, 2007
Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis; Treatment of osteoporosis in postmenopausal women
Dosage: INJECTABLE;INTRAVENOUS
How can I launch a generic of RECLAST before it's drug patent expiration?
More Information on Dosage
RECLAST family patents
2. Zometa patents expiration
ZOMETA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US4939130 | NOVARTIS | Substituted alkanediphosphonic acids and pharmaceutical use |
Sep, 2012
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US4939130 (Pediatric) | NOVARTIS | Substituted alkanediphosphonic acids and pharmaceutical use |
Mar, 2013
(11 years ago) | |
| US8324189 | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
May, 2025
(1 year, 1 month from now) | |
|
US8324189 (Pediatric) | NOVARTIS | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
Nov, 2025
(1 year, 7 months from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Sep 20, 2011 |
Market Authorisation Date: 20 August, 2001
Treatment: Hypercalcemia of malignancy
Dosage: INJECTABLE;INTRAVENOUS
How can I launch a generic of ZOMETA before it's drug patent expiration?
More Information on Dosage
ZOMETA family patents